Drugs / ODC-IL2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06770764 | Dec 2024 → Mar 2027 expected | metastatic neoplasm, neoplasm | Trutino Biosciences Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ODC-IL2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06770764 ↗ |
| Route | Intravenous | “administered as a single agent via intravenous infusion” NCT06770764 ↗ |